Valuation: Kamada Ltd.

Market Cap 1.28B 0 418M 364M 339M 311M 587M 39.94B 596M 3.99B 1.57B 19.89B 1.57B 1.54B 66.68B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.28B 0 418M 364M 339M 311M 587M 39.94B 596M 3.99B 1.57B 19.89B 1.57B 1.54B 66.68B EV / Sales 2026 *
2.14x
EV / Sales 2027 * 1.96x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
1 day+2.92%
1 week+2.96%
1 month-1.72%
3 months-8.36%
6 months-14.53%
Current year-1.59%
1 week 2,109
Extreme 2109
2,243
1 month 2,076
Extreme 2076
2,294
Current year 2,076
Extreme 2076
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 57 01/07/2015
Director of Finance/CFO 55 31/12/2017
Chief Operating Officer 53 01/11/2016
Director TitleAgeSince
Director/Board Member 75 13/12/1990
Chairman 77 07/03/2013
Chairman 55 12/08/2020
Date Insider Type Main position Quantity % Market Cap.
7/4/26 Free

General Counsel

198,970 0.3449%
7/4/26 Free

Director

60,000 0.1040%
16/3/26 Other

Chief Executive Officer

861,875 1.4942%
Change 5-day change 1-year change 3-year change Capi.($)
+2.92%+2.96%-12.68%+20.61% 418M
+3.29%+16.25%+36.46%+3.19% 76.15B
+2.72%-9.39%+20.58%+172.43% 48.89B
-2.75%+48.50%+48.50%+48.50% 47.83B
-3.81%+7.74%-53.40%-54.31% 41.37B
-2.40%+0.38%+53.81%-24.64% 29.99B
-2.82%+1.57%+58.12%+87.66% 24.23B
-5.35%+1.39%+98.59%-51.89% 21.75B
-1.59%-3.61%-6.77%+150.58% 19.25B
-0.42%+2.89%+77.99%+128.67% 17.14B
Average -1.02%+1.63%+32.12%+48.08% 32.7B
Weighted average by Cap. -0.61%+2.98%+31.38%+43.16%

Financials

2026 *2027 *
Net sales 600M 0 196M 170M 158M 145M 275M 18.69B 279M 1.87B 733M 9.3B 735M 719M 31.2B 655M 0 213M 186M 173M 159M 299M 20.38B 304M 2.04B 799M 10.15B 802M 784M 34.02B
Net income 73.89M 0 24.1M 20.95M 19.5M 17.9M 33.81M 2.3B 34.33M 230M 90.21M 1.15B 90.51M 88.52M 3.84B 105M 0 34.39M 29.89M 27.82M 25.54M 48.24M 3.28B 48.99M 328M 129M 1.63B 129M 126M 5.48B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
31/07/26 ILA 2,224.00 +2.92% 33,746
30/07/26 ILA 2,161.00 -0.05% 108,999
29/07/26 ILA 2,162.00 +2.32% 45,861
28/07/26 ILA 2,113.00 -0.28% 49,220
27/07/26 ILA 2,119.00 -1.90% 64,766
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock